U0126 and PD98059, Specific Inhibitors of MEK, Accelerate Differentiation of RAW264.7 Cells into Osteoclast-like Cells*

Osteoclasts are multinucleated cells that differentiate from hematopoietic cells and possess characteristics responsible for bone resorption. To study the involvement of mitogen-activated protein kinases (MAPKs) in osteoclastogenesis of the murine monocytic cell line RAW264.7, which can differentiate into osteoclast-like cells in the presence of the receptor activator of nuclear factor kappa B ligand (RANKL), we treated the cells with specific inhibitors of p38 MAPK, PD169316 and SB203580, and specific inhibitors of MAPK extracellular signaling-regulated kinase (ERK) kinase (MEK), U0126 and PD98059. Each inhibitor blocked differentiation into osteoclast-like cells when the cells were plated at the standard cell density (2000–4000 cells per well (96-well)). However, the effect of MEK inhibitors on osteoclastogenesis varied according to the initial cell density during culture, because cell growth was clearly inhibited by them. When the cells were plated at more than 8000 cells per well, marked enhancement and acceleration of the differentiation were observed. In addition, immunoblot analysis revealed that phosphorylation of ERK was increased by treatment with the p38 inhibitors, whereas the MEK inhibitors increased phosphorylation of p38, which implies a seesaw-like balance between ERK and p38 phosphorylation. We suggest that osteoclastogenesis is regulated under a balance between ERK and p38 pathways and that the MEK/ERK pathway negatively regulates osteoclastogenesis while the p38 pathway does so positively. This is the first report that an inhibitor of signal transduction enhanced osteoclastogenesis.

[1]  Min Huang,et al.  Inhibition of Nucleoside Transport by p38 MAPK Inhibitors* , 2002, The Journal of Biological Chemistry.

[2]  S. Cook,et al.  Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells , 1999, Oncogene.

[3]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[4]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[5]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Hunter,et al.  The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. , 2002, Molecular cell.

[7]  P. Cohen,et al.  Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. , 1992, The Biochemical journal.

[8]  L. Heasley,et al.  The beta-PDGF receptor induces neuronal differentiation of PC12 cells. , 1992, Molecular biology of the cell.

[9]  D. Lauffenburger,et al.  A Computational Study of Feedback Effects on Signal Dynamics in a Mitogen‐Activated Protein Kinase (MAPK) Pathway Model , 2001, Biotechnology progress.

[10]  B. Kwon,et al.  Receptor activator of NF‐κB recruits multiple TRAF family adaptors and activates c‐Jun N‐terminal kinase , 1999, FEBS letters.

[11]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[12]  M. Karin,et al.  Mammalian MAP kinase signalling cascades , 2001, Nature.

[13]  Z. Lee,et al.  The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. , 2002, Bone.

[14]  W. Dougall,et al.  The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-associated Factors in the Signaling Mechanisms of Receptor Activator of NF-κB, a Member of the TNFR Superfamily* , 1998, The Journal of Biological Chemistry.

[15]  K. Kanaoka,et al.  Fluorescence microscopic demonstration of cathepsin K activity as the major lysosomal cysteine proteinase in osteoclasts. , 1998, Journal of biochemistry.

[16]  R. Steinman,et al.  The TRAF Family of Signal Transducers Mediates NF-κB Activation by the TRANCE Receptor* , 1998, The Journal of Biological Chemistry.

[17]  Shi Wei,et al.  Interleukin-4 Reversibly Inhibits Osteoclastogenesis via Inhibition of NF-κB and Mitogen-activated Protein Kinase Signaling* , 2002, The Journal of Biological Chemistry.

[18]  F. Hobbs,et al.  Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.

[19]  Jiahuai Han,et al.  SB203580 promote EGF‐stimulated early morphological differentiation in PC12 cell through activating ERK pathway † , 2001, Journal of cellular biochemistry.

[20]  E. Van Obberghen,et al.  Differential activation of p44mapk (ERK1) by alpha-thrombin and thrombin-receptor peptide agonist. , 1993, The Biochemical journal.

[21]  R. Tuan,et al.  Cell density dependent regulation of AP‐1 activity is important for chondrogenic differentiation of C3H10T1/2 mesenchymal cells , 2002, Journal of cellular biochemistry.

[22]  Richard K. Assoian.  Common sense signalling , 2002, Nature Cell Biology.

[23]  M. Tsujimoto,et al.  Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)* , 2000, The Journal of Biological Chemistry.

[24]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[25]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[26]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[27]  C. Debouck,et al.  Cathepsin K, but Not Cathepsins B, L, or S, Is Abundantly Expressed in Human Osteoclasts (*) , 1996, The Journal of Biological Chemistry.

[28]  R. Baron,et al.  Osteoclasts express high levels of pp60c-src in association with intracellular membranes , 1992, The Journal of cell biology.

[29]  P. Cohen,et al.  EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor , 1994, Current Biology.

[30]  Allan Bradley,et al.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.

[31]  G. Bilbe,et al.  Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. , 1995, Biochemical and biophysical research communications.

[32]  A. Brunet,et al.  Growth factor‐stimulated MAP kinase induces rapid retrophosphorylation and inhibition of MAP kinase kinase (MEK1) , 1994, FEBS letters.

[33]  S. Cook,et al.  Kinetic and biochemical correlation between sustained p44ERK1 (44 kDa extracellular signal-regulated kinase 1) activation and lysophosphatidic acid-stimulated DNA synthesis in Rat-1 cells. , 1996, The Biochemical journal.

[34]  Reinhart Heinrich,et al.  Mathematical models of protein kinase signal transduction. , 2002, Molecular cell.

[35]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  K. Chihara,et al.  Dexamethasone Stimulates Osteoclast‐like Cell Formation by Directly Acting on Hemopoietic Blast Cells and Enhances Osteoclast‐like Cell Formation Stimulated by Parathyroid Hormone and Prostaglandin E2 , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  T. Martin,et al.  Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Van Obberghen,et al.  Co-regulation of the mitogen-activated protein kinase, extracellular signal-regulated kinase 1, and the 90-kDa ribosomal S6 kinase in PC12 cells. Distinct effects of the neurotrophic factor, nerve growth factor, and the mitogenic factor, epidermal growth factor. , 1993, The Journal of biological chemistry.

[39]  Rey-Huei Chen,et al.  Molecular interpretation of ERK signal duration by immediate early gene products , 2002, Nature Cell Biology.

[40]  J. Baldassare,et al.  Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. , 1997, The Biochemical journal.

[41]  D L Lacey,et al.  RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Bottazzi,et al.  α5β1 Integrin Controls Cyclin D1 Expression by Sustaining Mitogen-activated Protein Kinase Activity in Growth Factor-treated Cells , 1999 .

[43]  H. Hanafusa,et al.  TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. , 1999, Molecular cell.

[44]  B. Aggarwal,et al.  Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. , 1999, The Journal of biological chemistry.

[45]  H. Yasuda,et al.  RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.